Tweets
Dr. @drpnash @RheumNow
➡️Difficult to treat Axial SpA ;
23,0000 🧍♀️🧍:
1-Failure of 3 biolo - targ synth, or different mechanism of action.
2- Around 10% of patients.
1-Female.
2-Peripheral arthritis.
3-Psoriasis
4-Lipid , HTN, Smoking.
https://t.co/B99TcXjjiF…
#ACR23
Nouf Al hemmadi ( View Tweet )
2 years 7 months ago
Got to get a pic with the very busy man Dr @RheumNow John “Jack” Cush at his booth at @ACRheum #ACR23 #ACRambassador . Make sure to follow RheumNow to keep up on important rheum matters https://t.co/rgWvRr0Dln
Donald Thomas, MD @lupuscyclopedia ( View Tweet )
2 years 7 months ago
The ADIRA trial showed no significant difference in change in DAS28 bet grps in the adjusted analysis.
Intervention included food delivery svc & probiotic shot
Limitations included study design issues such small sample size
#ACR23 @RheumNow @rheumarhyme https://t.co/J6LEb0yONS
sheila ( View Tweet )
2 years 7 months ago
Don’t forget:
👉anti-HMGCR Ab in patients with immune mediated necrotizing myositis (may be assc with statins)
👉Anti-synthetase Ab assc with ILD, anti-synthetase syndrome #Rheum #BoardQuestion https://t.co/pBAADeR9ON
TheDaoIndex @KDAO2011 ( View Tweet )
2 years 7 months ago
Persistence of IL-17i vs. TNFi in PsA treatment
Large database study
Persistence of IL-17i slightly greater than TNFi over 12 months
Are IL-17i a better longterm strategy for PsA pts?
@RheumNow #ACR23 Abs# 2240 https://t.co/9km5XgXcLE
Robert B Chao, MD ( View Tweet )
2 years 7 months ago
#VEXAS is still hot at #ACR23 - 245K whole genome sequencing data from #NIH All of US - 74 with somatic mutation UBA1
Increased asthma, Tietze’s syndrome and neutropenia
Hemoglobin similar in cases and controls
@rheumnow #abstL03 https://t.co/A374w60e6H
Bella Mehta @bella_mehta ( View Tweet )
2 years 7 months ago
Review of the limitations and possible toxicities with CAR-T treatment. ICANs and CRS, while treatable, are very important to educate and understand. This is part of the intersection of heme/onc and rheum. https://t.co/itbwLdHuqf
Dr. Rachel Tate ( View Tweet )
2 years 7 months ago
RheumNow’s expanded coverage of the #ACR23 is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
Rector et al. Pregnancy outcomes in vasculitis. More spontaneous abortion, elective termination, ectopic & molar pregnancy, x2 preterm delivery. Preeclampsia in 12%. Worse again in small vessel vasculitis Abstr#2425 #ACR23 @RheumNow https://t.co/cotncE16ma https://t.co/QoJpJIHJfJ
Richard Conway ( View Tweet )
2 years 7 months ago
#ACRBest https://t.co/nx3bzhmeBW
Aurelie Najm ( View Tweet )
2 years 7 months ago
There is a dose, duration and recency-dependent relationship between previous GC use and MACE. GC doses 5mg/day, durations of 30 days, and use one year prior to MACE were all associated with an increased risk of MACE, Wallace B Abst#2430 #ACR23 #ACRBest https://t.co/2ExboBvo2W https://t.co/FuqXdFFwqP
Dr. Antoni Chan ( View Tweet )
2 years 7 months ago
What % of pts in #RCTs in #SLE go in to #LLDAS - Pooling 5 RCTs - starting on #belimumab vs #placebo? More w #bDMARD @RheumNow @ACRheum #ACR23 abst#2551. True w DORIS - #lupus #rem but overall lower rates in each group https://t.co/VPZrYCVjof
Janet Pope ( View Tweet )
2 years 7 months ago
